



**News Flash** - The April 2009 version of the *Medicare Disproportionate Share Hospital Fact Sheet* is now available in downloadable format from the Centers for Medicare & Medicaid Services Medicare Learning Network at [http://www.cms.hhs.gov/MLNProducts/downloads/2009\\_mdsh.pdf](http://www.cms.hhs.gov/MLNProducts/downloads/2009_mdsh.pdf) on the CMS website. This fact sheet provides information about methods to qualify for the Medicare Disproportionate Share Hospital (DSH) adjustment; Medicare Prescription Drug, Improvement, and Modernization Act of 2003 and Deficit Reduction Act of 2005; number of beds in hospital determination; and Medicare DSH payment adjustment formulas.

MLN Matters Number: MM6094

Related Change Request (CR) #: 6094

Related CR Release Date: June 19, 2008

Effective Date: July 1, 2008

Related CR Transmittal #: R1536CP and R90BP

Implementation Date: July 7, 2008

## July 2008 Update of the Hospital Outpatient Prospective Payment System (OPPS)

### Provider Types Affected

Providers submitting claims to Medicare contractors (Fiscal Intermediaries (FIs), Regional Home Health Intermediaries (RHHIs), and/or Part A/B Medicare Administrative Contractors (A/B MACs)) for services provided to Medicare beneficiaries that are paid under the OPPS.

### Provider Action Needed

This article is based on CR6094, which describes changes to, and billing instructions for various payment policies implemented in the July 2008 OPPS update. The July 2008 Integrated Outpatient Code Editor (I/OCE) and OPPS PRICER will reflect the Healthcare Common Procedure Coding System (HCPCS), Ambulatory Payment Classification (APC), HCPCS Modifier, and Revenue Code additions, changes, and deletions identified in this notification.

The July 2008 revisions to the I/OCE data files, instructions, and specifications are discussed in MLN Matters article MM6080, which is available at

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

<http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM6080.pdf> on the Centers for Medicare & Medicaid Services (CMS) website. Be sure your billing staff is aware of these changes.

## Background

---

Following are the key changes effective for July 1, 2008 update of the OPPS:

### *Applicability of OPPS to Specific HCPCS Codes*

Current Procedural Terminology (CPT) codes generally are created to describe and report physician services, but are also used by other providers/suppliers to describe and report services that they provide. Therefore, the CPT code descriptors do not necessarily reflect the facility component of a service furnished by the hospital. Some CPT code descriptors include reference to a physician performing a service. For OPPS purposes, unless indicated otherwise, the usage of the term "physician" does not restrict the reporting of the code or application of related policies to physicians only but applies to all practitioners, hospitals, providers, or suppliers eligible to bill the relevant CPT codes pursuant to applicable portions of the Social Security Act (SSA) of 1965, the Code of Federal Regulations (CFR), and Medicare rules. In cases where there are separate codes for the technical component, professional component, and/or complete procedure, hospitals should report the code that represents the technical component for their facility services. If there is no separate technical component code for the service, hospitals should report the code that represents the complete procedure.

### *Changes to Procedure and Device Edits for July 2008*

Procedure to device edits require that when a particular procedural HCPCS code is billed, the claim must also contain an appropriate device code. Failure to pass these edits will result in the claim being returned to the provider. Device to procedure edits require that a claim that contains one of a specified set of device codes be returned to the provider if it fails to contain an appropriate procedure code. The updated lists of both types of edits can be found under "2008 Device and Procedure Edits" at <http://www.cms.hhs.gov/HospitalOutpatientPPS/> on the CMS website.

### *Payment for Brachytherapy Sources as of July 1, 2008*

The Medicare, Medicaid, and SCHIP Extension Act of 2007 requires CMS to pay for brachytherapy sources for the period of January 1 through June 30, 2008, at hospitals' charges adjusted to the costs. Therefore, the CMS is paying for brachytherapy sources based on charges adjusted to cost through June 30, 2008, and CMS will pay at prospective rates as of July 1, 2008. The prospective payment rates for each source, which are listed in Addendum B to the CY 2008 final rule dated November 27, 2007, will be used for payment from July 1 through December 31, 2008. (Addendum B is available at <http://www.cms.hhs.gov/HospitalOutpatientPPS/AU/list.asp> on the CMS website.) The "H" payment status indicators of brachytherapy source HCPCS codes (except C2637), which were previously paid at charges adjusted to cost, will change to payment status indicator "K" effective July 1, 2008 through December 31, 2008.

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

In addition, because the sources will be paid based on prospective rates as of July 1, brachytherapy sources will be eligible for outlier payments and for the rural sole community hospital (SCH) adjustment as of July 1, 2008. The HCPCS codes for separately payable brachytherapy sources, long descriptors, status indicators, and APCs for CY 2008 are listed in Table 1 below, a comprehensive list of payable brachytherapy sources. Note that when billing for stranded sources, providers should bill the number of units of the appropriate source HCPCS C-code according to the number of brachytherapy sources in the strand, and should not bill as one unit per strand. See MLN Matters article MM5623 at <http://www.cms.hhs.gov/MLNMattersArticles/downloads/MM5623.pdf> for further information on billing for brachytherapy sources and the OPSS coding changes made for brachytherapy sources effective July 1, 2007.

**Table 1- Comprehensive List of Brachytherapy Sources Payable as of July 1, 2008**

CPT/ HCPCS	Long Descriptor	**SI	APC
A9527	Iodine I-125, sodium iodide solution, therapeutic, per millicurie	K	2632
C1716	Brachytherapy source, non-stranded, Gold-198, per source	K	1716
C1717	Brachytherapy source, non-stranded, High Dose Rate Iridium-192, per source	K	1717
C1719	Brachytherapy source, non-stranded, Non-High Dose Rate Iridium-192, per source	K	1719
C2616	Brachytherapy source, non-stranded, Yttrium-90, per source	K	2616
C2634	Brachytherapy source, non-stranded, High Activity, Iodine-125, greater than 1.01 mCi (NIST), per source	K	2634
C2635	Brachytherapy source, non-stranded, High Activity, Palladium-103, greater than 2.2 mCi (NIST), per source	K	2635
C2636	Brachytherapy linear source, non-stranded, Palladium-103, per 1MM	K	2636
C2638	Brachytherapy source, stranded, Iodine-125, per source	K	2638
C2639	Brachytherapy source, non-stranded, Iodine-125, per source	K	2639
C2640	Brachytherapy source, stranded, Palladium-103, per source	K	2640
C2641	Brachytherapy source, non-stranded, Palladium-103, per source	K	2641
C2642	Brachytherapy source, stranded, Cesium-131, per source	K	2642
C2643	Brachytherapy source, non-stranded, Cesium-131, per source	K	2643
C2698	Brachytherapy source, stranded, not otherwise specified, per source	K	2698
C2699	Brachytherapy source, non-stranded, not otherwise specified, per source	K	2699

\*\* SI (Status Indicator)

### ***Continuous Positive Airway Pressure (CPAP) Therapy***

CMS revised its National Coverage Determination (NCD) for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA). CMS now allows coverage of CPAP when

#### **Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

used in adult patients diagnosed with obstructive sleep apnea (OSA) by home sleep testing (HST). This revised coverage became effective for claims with dates of service on and after March 13, 2008. Information on the criteria for coverage under this revised NCD can be found in section 240.4 of the NCD Manual, available at <http://www.cms.hhs.gov/manuals/IOM/list.asp> on the CMS website. To adequately report the home sleep study test for CPAP therapy, CMS has created the following three G-codes. Under OPPS, the G-codes have been assigned to APC 0213 (Level I Extended EEG and Sleep Studies). Payment rates for these services can be found in Addendum B of the July 2008 OPPS Update that is posted on the CMS website.

**Table 2-Home Sleep Study Tests for Continuous Positive Airway Pressure (CPAP) Therapy Services that are Effective July 1, 2008**

HCPCS	Long Descriptor	APC	SI
G0398	Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG, EOG, EMG, ECG/heart rate, airflow, respiratory effort and oxygen saturation	0213	S
G0399	Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1 oxygen saturation	0213	S
G0400	Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels	0213	S

### *Category III CPT Codes*

The American Medical Association (AMA) releases Category III CPT codes in January, for implementation beginning the following July, and in July, for implementation beginning the following January. Prior to CY 2006, CMS implemented new Category III CPT codes once a year in January of the following year. As discussed in the CY 2006 OPPS final rule with comment period (70 FR 68567), CMS modified the process for implementing the Category III codes that the AMA releases each January for implementation in July to ensure timely collection of data pertinent to the services described by the codes; to ensure patient access to the services the codes describe; and to eliminate potential redundancy between Category III CPT codes and some of the C-codes that are payable under the OPPS and were created by CMS in response to applications for new technology services. Therefore, on July 1, 2008, CMS implemented in the OPPS five Category III CPT codes that the AMA released in January 2008 for implementation in July 2008. The codes, along with their status indicators and APCs, are shown in Table 3 below. Payment rates for these services can be found in Addendum B of the July 2008 OPPS Update that is posted on the CMS website.

**Table 3--Category III CPT Codes Implemented as of July 1, 2008**

HCPCS	Long Descriptor	APC	SI
0188T	Remote real-time interactive videoconferenced critical care, evaluation and management of the critically ill or critically injured patient; first 30-	N/A	M

#### Disclaimer

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

HCPCS	Long Descriptor	APC	SI
	74 minutes		
0189T	Remote real-time interactive videoconferenced critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes	N/A	M
0190T	Placement of intraocular radiation source applicator	0237	T
0191T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; internal approach	0234	T
0192T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; external approach	0234	T

### ***Cardiac Echocardiography With Contrast (C8921 - C8928)***

In the April 2008 update to the OPPS, CMS listed the revised short and long descriptors for the eight new C-codes for cardiac echocardiography with contrast services that were effective January 1, 2008. The codes, along with the revised short and long descriptors, were listed in Table 3. Unfortunately, the long descriptors for C8922 and C8924 were incorrect in Table 3. The correct short and long descriptors for the eight C-codes for cardiac echocardiography with contrast services were posted on the CMS HCPCS website, specifically at [http://www.cms.hhs.gov/HCPCSReleaseCodeSets/02\\_HCPCS\\_Quarterly\\_Update.asp#TopOfPage](http://www.cms.hhs.gov/HCPCSReleaseCodeSets/02_HCPCS_Quarterly_Update.asp#TopOfPage) on the CMS website. Refer to the April 2008 HCPCS C-codes list dated March 25, 2008. **Hospitals are advised to download this file to view the correct long descriptors for C8922 and C8924.**

### ***Billing for Drugs, Biologicals, and Radiopharmaceuticals***

Hospitals are strongly encouraged to report charges for all drugs, biologicals, and radiopharmaceuticals, regardless of whether the items are paid separately or packaged, using the correct HCPCS codes for the items used. It is also of great importance that hospitals billing for these products make certain that the reported units of service of the reported HCPCS code are consistent with the quantity of a drug, biological, or radiopharmaceutical that was used in the care of the patient.

CMS reminds hospitals that under the OPPS, if two or more drugs or biologicals are mixed together to facilitate administration, the correct HCPCS codes should be reported separately for each product used in the care of the patient. The mixing together of two or more products does not constitute a "new" drug as regulated by the Food and Drug Administration (FDA) under the New Drug Application (NDA) process. In these situations, hospitals are reminded that it is not appropriate to bill HCPCS code C9399. HCPCS code C9399, Unclassified drug or biological, is for new drugs and biologicals that are approved by the FDA on or after January 1, 2004, for which a HCPCS code has not been assigned.

#### **Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

Unless otherwise specified in the long description, HCPCS descriptions refer to the non-compounded, FDA-approved final product. If a product is compounded and a specific HCPCS code does not exist for the compounded product, the hospital should report an appropriate unlisted code such as J9999 or J3490.

**a. Drugs and Biologicals with Payments Based on Average Sales Price (ASP) Effective July 1, 2008**

In the CY 2008 OPSS final rule, it was stated that payments for separately payable drugs and biologicals based on average sale prices (ASPs) will be updated on a quarterly basis as later quarter ASP submissions become available. In cases where adjustments to payment rates are necessary based on the most recent ASP submissions, CMS will incorporate changes to the payment rates in the July 2008 release of the OPSS PRICER. The updated payment rates effective July 1, 2008, will be included in the July 2008 update of the OPSS Addendum A and Addendum B, which will be posted at <http://www.cms.hhs.gov/HospitalOutpatientPPS/AU/list.asp> on the CMS website shortly.

**b. Drugs and Biologicals with OPSS Pass-Through Status Effective July 1, 2008**

Six drugs have been granted OPSS pass-through status effective July 1, 2008. These drugs, their descriptors, and APC assignments are identified in Table 4 below.

**Table 4- Drugs Granted Pass-Through Status Effective July 1, 2008**

HCPCS	Long Descriptor	SI	APC
C9242*	Injection, fosaprepitant, 1 mg	G	9242
C9356*	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per square centimeter	G	9356
C9357*	Dermal substitute, granulated cross-linked collagen and glycosaminoglycan matrix (Flowable Wound Matrix), 1 cc	G	9357
C9358*	Dermal substitute, native, non-denatured collagen (SurgiMend Collagen Matrix), per 0.5 square centimeters	G	9358
J1571	Injection, hepatitis b immune globulin (Hepagam b), intramuscular, 0.5 ml	G	0946
J1573	Injection, hepatitis b immune globulin (Hepagam b), intravenous, 0.5 ml	G	1138

**Note:** Those HCPCS codes identified with a "\*" indicate that they are new codes effective July 1, 2008.

**c. Updated Payment Rates for Certain HCPCS Codes Effective October 1, 2007 through December 31, 2007**

The payment rates for several HCPCS codes were incorrect in the October 2007 OPSS Pricer. The corrected payment rates are listed below and have been installed in the July

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

2008 OPSS Pricer, effective for services furnished on October 1, 2007, through implementation of the January 2008 update. Your Medicare contractor will adjust any claims that you bring to their attention that were not processed correctly due to the incorrect rates in the October 2007 OPSS Pricer.

**Table 5- Updated Payment Rates for Certain HCPCS Codes Effective October 1, 2007 through December 31, 2007**

HCPCS	APC	Short Descriptor	Corrected Payment Rate	Corrected Minimum Unadjusted Copayment
90371	1630	Hep b ig, im	121.28	24.26
90675	9139	Rabies vaccine, im	152.82	30.56
J0637	9019	Caspofungin acetate	24.29	4.86
J1562	0804	Vivaglobulin, injection	7.01	1.40
J9015	0807	Aldesleukin/single use vial	758.15	151.63

**d. Updated Payment Rates for Certain HCPCS Codes Effective January 1, 2008 through March 31, 2008**

The payment rates for several HCPCS codes were incorrect in the January 2008 OPSS Pricer. The corrected payment rates are listed below and have been installed in the July 2008 OPSS Pricer, effective for services furnished on January 1, 2008, through implementation of the April 2008 update. Your Medicare contractor will adjust any claims that you bring to their attention that were not processed correctly due to the incorrect rates in the January 2008 OPSS Pricer.

**Table 6- Updated Payment Rates for Certain HCPCS Codes Effective January 1, 2008 through March 31, 2008**

HCPCS	APC	Short Descriptor	Corrected Payment Rate	Corrected Minimum Unadjusted Copayment
90675	9139	Rabies vaccine, im	150.27	30.05
J2820	0731	Sargramostim injection	25.02	5.00
J9010	9110	Alemtuzumab injection	549.29	109.86
J9015	0807	Aldesleukin/single use vial	764.56	151.47
J9226	1142	Supprelin LA implant	14694.12	2938.82

**e. Updated Payment Rates for Certain HCPCS Codes Effective April 1, 2008 through June 30, 2008**

The payment rates for several HCPCS codes were incorrect in the April 2008 OPSS Pricer. The corrected payment rates are listed below and have been installed in the July

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

2008 OPPS Pricer, effective for services furnished on April 1, 2008, through implementation of the July 2008 update. Your Medicare contractor will adjust any claims that you bring to their attention that were not processed correctly due to the incorrect rates in the April 2008 OPPS Pricer.

**Table 7- Updated Payment Rates for Certain HCPCS Codes Effective April 1, 2008 through June 30, 2008**

HCPCS	APC	Short Descriptor	Corrected Payment Rate	Corrected Minimum Unadjusted Copayment
J2323	9126	Natalizumab injection	7.51	1.49
J2778	9233	Ranibizumab inj	406.18	80.47
J3488	0951	Reclast injection	216.61	42.91

#### **f. Correct Reporting of Drugs and Biologicals When Used As Implantable Devices**

Hospitals are not to bill separately for drug and biological HCPCS codes, with the exception of drugs and biologicals with pass-through status, when using these items as implantable devices (including as a scaffold or an alternative to human or nonhuman connective tissue or mesh used in a graft) during surgical procedures. Under the OPPS, hospitals are provided a packaged APC payment for surgical procedures that includes the cost of supportive items, including implantable devices without pass-through status. When using drugs and biologicals during surgical procedures as implantable devices, hospitals may include the charges for these items in their charge for the procedure, report the charge on an uncoded revenue center line, or report the charge under a device HCPCS code (if one exists) so these costs would appropriately contribute to the future median setting for the associated surgical procedure.

#### **g. Correct Reporting of Units for Drugs**

Hospitals and providers are reminded to ensure that units of drugs administered to patients are accurately reported in terms of the dosage specified in the full HCPCS code descriptor. That is, units should be reported in multiples of the units included in the HCPCS descriptor. For example, if the description for the drug code is 6 mg, and 6 mg of the drug was administered to the patient, the units billed should be 1. As another example, if the description for the drug code is 50 mg but 200 mg of the drug was administered to the patient, the units billed should be 4. Providers and hospitals should not bill the units based on the way the drug is packaged, stored, or stocked. That is, if the HCPCS descriptor for the drug code specifies 1 mg and a 10 mg vial of the drug was administered to the patient, bill 10 units, even though only 1 vial was administered. HCPCS short descriptors are limited to 28 characters, including spaces, so short descriptors do not always capture the complete description of the drug. Therefore, before submitting Medicare claims for drugs and biologicals, it is extremely important to review the complete long descriptors for the applicable HCPCS codes.

#### **h. Changes to Payment for Therapeutic Radiopharmaceuticals for July 2008**

##### **Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

The Medicare, Medicaid, and State Children's Health Insurance Program Extension Act of 2007, Pub. L. No. 110-173 amended the Medicare statute and provided a continuation of payment for therapeutic radiopharmaceuticals based on individual hospital charges adjusted to cost from January 1 through June 30, 2008. Therefore, in accordance with the statute, finalized CY 2008 prospective payment rates for therapeutic radiopharmaceuticals were not implemented in the OPSS during this time period. However, the statute expires on June 30, 2008, and, as such, the finalized payment prospective payment rates go into effect on July 1, 2008. Therefore, payment for separately payable therapeutic radiopharmaceuticals under the OPSS will be made on a prospective basis, with payment rates based upon mean costs from hospital claims data as set forth in the CY 2008 OPSS/ASC final rule (72 FR 66772), beginning on July 1, 2008.

**Table 8-Therapeutic Radiopharmaceuticals that are Separately Payable Effective July 1, 2008**

HCCPS	Long Descriptor	SI	APC
A9517	Iodine I-131 sodium iodide capsule(s), therapeutic, per millicurie	K	1064
A9530	Iodine I-131 sodium iodide solution, therapeutic, per millicurie	K	1150
A9543	Yttrium Y-90 ibritumomab tiuxetan, therapeutic, per treatment dose, up to 40 millicuries	K	1643
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	K	1645
A9563	Sodium phosphate P-32, therapeutic, per millicurie	K	1675
A9564	Chromic phosphate P-32 suspension, therapeutic, per millicurie	K	1676
A9600	Strontium Sr-89 chloride, therapeutic, per millicurie	K	0701
A9605	Samarium Sm-153 lexidronamm, therapeutic, per 50 millicuries	K	0702

**i. Changes to Nuclear Medicine Procedure to Radiopharmaceutical Edits for July 2008**

Effective January 1, 2008, under the OPSS, payment for diagnostic radiopharmaceuticals is packaged into payment for their associated nuclear medicine procedures. In order to ensure that appropriate diagnostic radiopharmaceutical costs for future rate setting purposes was captured, CMS implemented edits in the I/OCE effective January 2008 that required a diagnostic radiopharmaceutical to be present on the same claim as a nuclear medicine procedure.

**Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

As is the standard process for edit lists under the OPPS, CMS reviews the appropriateness of the edits and considers modifying the edits quarterly as issues are brought to their attention. In April 2008, in response to several descriptions of specific clinical scenarios provided to CMS by members of the public, CMS added HCPCS code A9517 (Iodine I-131 sodium iodide capsule(s), therapeutic, per millicurie) to their list of radiopharmaceuticals that would be accepted for a nuclear medicine procedure claim to process.

Since the change to the edit list was adopted for the April update, CMS has received several descriptions of clinical scenarios where a therapeutic radiopharmaceutical or a brachytherapy source is provided to a patient by a hospital and a nuclear medicine procedure follows, without administration of a diagnostic radiopharmaceutical. Members of the public bringing these situations to the attention of CMS state that situations where these radiolabeled products would be used without a diagnostic radiopharmaceutical would be rare, but are sufficiently common that hospitals require a methodology to appropriately bill and be paid for the associated nuclear medicine procedures. As a result of these requests, for the July 2008 update CMS has included the HCPCS codes for all diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, and brachytherapy sources as radiolabeled products that may be reported on a claim with nuclear medicine procedures to satisfy the edit requirements. CMS expects that the majority of nuclear medicine procedures will be performed with diagnostic radiopharmaceuticals, and that it will be only in uncommon circumstances that hospitals would report nuclear medicine procedures with therapeutic radiopharmaceuticals or brachytherapy sources. CMS will be monitoring claims to ensure that this is the case.

Therefore, beginning in July 2008, claims for nuclear imaging procedures reported with any of the HCPCS codes for diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals, or brachytherapy sources will not be returned to the provider as the nuclear medicine procedure and radiolabeled product are included on the same claim.

**Note:** Hospitals are only to report HCPCS codes for products they administer and should not be reporting a token charge for a radiolabeled product on the edit list solely for the purpose of bypassing edits present in the I/OCE.

The complete list of updated edits can be found at [http://www.cms.hhs.gov/HospitalOutpatientPPS/02\\_device\\_procedure.asp#TopOfPage](http://www.cms.hhs.gov/HospitalOutpatientPPS/02_device_procedure.asp#TopOfPage) on the CMS website.

### ***Hospital Services for Patients with End Stage Renal Disease (ESRD)***

CMS is revising the Medicare Claims Processing Manual, Chapter 4, Section 200.2 to expand the circumstances under which payment may be made to a hospital for unscheduled outpatient dialysis provided to an ESRD patient. The first circumstance listed is "dialysis performed following or in connection with a vascular access procedure". CMS is expanding this to include any dialysis

#### **Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.

related procedure such as vascular access procedures or blood transfusions, and the revised Chapter 4 (Section 200.2) of the Medicare Claims Processing Manual is included as an attachment to CR 6094.

### ***Coverage of Outpatient Therapeutic Services Incident to a Physician's Service Furnished on or After August 1, 2000***

CMS is revising the Medicare Benefit Policy Manual, Chapter 6, Section 20.5.1 to remove language stating that services furnished in provider-based departments of hospitals must be rendered under the direct supervision of a physician "who is treating the patient." While this "treating the patient" language has been a part of the manual for several years, recent revisions made to Section 20.5.1 in Transmittal 82/CR 5946 (February 8, 2008) have caused confusion related to the context and application of this phrase in relation to the requirements of the Code of Federal Regulations. The revised Chapter 6 (Section 20.5.1) of the Medicare Benefit Policy Manual is included as an attachment to CR 6094.

### ***Coverage Determinations***

The fact that a drug, device, procedure or service is assigned a HCPCS code and a payment rate under the OPSS does not imply coverage by the Medicare program, but indicates only how the product, procedure, or service may be paid if covered by the program. FIs/AB MACS will determine whether a drug, device, procedure, or other service meets all program requirements for coverage. For example, FI/MACs will determine that it is reasonable and necessary to treat the beneficiary's condition and whether it is excluded from payment.

## **Additional Information**

---

The official instruction, CR 6094, issued to your FI, RHHI, and A/B MAC regarding this change may be viewed at <http://www.cms.hhs.gov/Transmittals/downloads/R1536CP.pdf> on the CMS website. The modified section of the Medicare Benefit Policy Manual regarding coverage of outpatient therapeutic services incident to physician's services is available at <http://www.cms.hhs.gov/Transmittals/downloads/R90BP.pdf> on the same site.

If you have any questions, please contact your FI, RHHI, or A/B MAC at their toll-free number, which may be found at <http://www.cms.hhs.gov/MLNProducts/downloads/CallCenterTollNumDirectory.zip> on the CMS website.

#### **Disclaimer**

This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2007 American Medical Association.